Early Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Safety and Efficacy of Intravitreal Conbercept Injection After Vitrectomy for the Treatment of Early Proliferative Diabetic Retinopathy
To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the
management of early-stage proliferative diabetic retinopathy (PDR).
Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from
PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual
outcomes of surgery for early-stage PDR.
The drug conbercept (an anti-vascular endothelial growth factors) was recently made available
for management of early prolific diabetic retinopathy, but its safety and efficacy still
require study. Therefore, the aim is to evaluate the safety and efficacy of intravitreal
conbercept after vitrectomy for the management of early proliferative diabetic
retinopathy.The patients were randomly assigned (25 eyes each group) to either treatment
group and control after they provided informed consent. The treatment group received
intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery, while the control group
did not.
At the time of study enrollment, physical examinations, best-corrected visual acuity (BCVA),
intraocular pressure and central retinal thickness will be measured and fundoscopy be
performed.
The patients are going to be followed up for at least 6 months via BCVA measurement,
fundoscopy, OCT, physical examinations and postoperative complications
;